KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer

作者：Haiyue Zhao, Ensong Guo, Ting Hu, Qian Sun, Jianli Wu, Xingguang Lin, Danfeng Luo, Chaoyang Sun, Changyu Wang, Bo Zhou, Na Li, Meng Xia, Hao Lü, Meng Li, Xiaoyan Xu, Junbo Hu, Ding Ma, Gang Chen, Tao Zhu · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.9721 · 被引用次数：35 · 研究领域：RNA modifications and cancer、RNA Research and Splicing、MicroRNA in disease regulation

// Haiyue Zhao 1, * , Ensong Guo 1, * , Ting Hu 1 , Qian Sun 1 , Jianli Wu 1 , Xingguang Lin 1 , Danfeng Luo 1 , Chaoyang Sun 1 , Changyu Wang 1 , Bo Zhou 1 , Na Li 1 , Meng Xia 1 , Hao Lu 1 , Li Meng 1 , Xiaoyan Xu 1 , Junbo Hu 1 , Ding Ma 1 , Gang Chen 1 , Tao Zhu 1 1 Cancer Biology Research Center (Key Laboratory of the Ministry Of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China * These authors have contributed equally to this work Correspondence to: Tao Zhu, email: tjogzt@gmail.com Gang Chen, email: chengang@tjh.tjmu.edu.cn Keywords: serous ovarian cancer, recurrence, prognosis, KCNN4 , S100A14 Received: November 26, 2015     Accepted: May 8, 2016     Published: May 30, 2016 ABSTRACT Approximately 50-75% of patients with serous ovarian carcinoma (SOC) experience recurrence within 18 months after first-line treatment. Current clinical indicators are inadequate for predicting the risk of recurrence. In this study, we used 7 publicly available microarray datasets to identify gene signatures related to recurrence in optimally debulked SOC patients, and validated their expressions in an independent clinic cohort of 127 patients using immunohistochemistry (IHC). We identified a two-gene signature including KCNN4 and S100A14 which was related to recurrence in optimally debulked SOC patients. Their mRNA expression levels were positively correlated and regulated by DNA ...